LEHI, UTAH, March 18, 2023 – Civica Inc. (Civica, Civica Rx) today announced it will manufacture insulins for the State of California’s CalRx Biosimilar Insulin Initiative as part of its insulin manufacturing work. Once approved, Civica’s biosimilar versions of the most commonly used short-and long-acting insulins will be available to Californians and nationwide at...

Civica, today announced the selection of Ypsomed AG as the manufacturer and supplier of insulin dosing injector pens for Civica’s affordable insulins. As previously announced, Civica plans to produce three insulin biosimilars – glargine, lispro and aspart – each of which will be available both in vials and prefilled pens, and sell the insulins at...

Starting today, global healthcare company AmerisourceBergen will serve as Civica, Inc.’s (Civica) exclusive distribution partner and provide supply chain support for Civica’s products and a best-in-class customer experience for Civica members. Through its distribution network, AmerisourceBergen will work to ensure that Civica’s crucial products reach its members across the country efficiently, reliably, and securely....

Governor Glenn Youngkin today announced that non-profit Civica Inc. (Civica) will invest $27.8 million to establish a new laboratory testing facility at Meadowville Technology Park in Chesterfield County. The company will construct a 55,000-square-foot facility to support Civica’s Petersburg pharmaceutical manufacturing operation through quality testing and development of new products. The project will create 51 new...

On this National Essential Medicine Shortage Awareness Day, September 8, we redouble our commitment to make quality essential medicines available and affordable to everyone. The shortage of medicines – including those used in emergency room care, the ICU, pain management, blood pressure control, and sedation – means unstable supplies for patient care and unpredictable...

CivicaScript, a public benefit company dedicated to bringing lower-cost generic medicines to U.S. consumers, today announced the availability of its first product: abiraterone acetate 250 mg tablets. Abiraterone is used together with steroid medication (prednisone) to treat prostate cancer that has spread to other parts of the body. Starting today, CivicaScript will offer abiraterone...

Navitus Health Solutions, an industry-disrupting pharmacy benefit manager (PBM) committed to bringing humanity to pharmacy benefits management through greater transparency and affordability, and CivicaScript, a statutory public benefit company dedicated to bringing lower-cost generic medicines to U.S. consumers, announced today that Navitus has joined CivicaScript as a founding member. This new partnership will enable...

Civica, Inc. (Civica Rx) announced today it has joined a new coalition of diverse stakeholders to address drug shortages in the United States. The End Drug Shortages Alliance provides a forum for key stakeholders to take strategic aim at one of health care’s more pressing and enduring issues, drug shortages that disrupt patient care....

CivicaScript, which is dedicated to bringing lower-cost generic medicines to U.S. consumers, and EmsanaRx, PBC, the only pharmacy benefit manager built by employers, for employers, announced today that EmsanaRx is joining CivicaScript as a partnering member. The partnership will make CivicaScript medicines available to EmsanaRx’s self-funded employer members. “We welcome the partnership of EmsanaRx as...

Civica, Inc. announces the selection of Profil, Neuss, Germany, as its clinical trial partner to support the development of its affordable insulins. As previously announced, Civica plans to produce three insulin biosimilars – glargine, lispro and aspart – each of which will be available both in vials and prefilled pens, and sell the insulins...